Literature DB >> 1548754

Human cytotoxic T cells stimulated by antigen on dendritic cells recognize the N, SH, F, M, 22K, and 1b proteins of respiratory syncytial virus.

A H Cherrie1, K Anderson, G W Wertz, P J Openshaw.   

Abstract

We examined the human cytotoxic T-cell repertoire of nine adults to 9 of the 10 proteins of respiratory syncytial (RS) virus. Peripheral blood mononuclear cells from normal adults were stimulated with RS virus in vitro. The resulting polyclonal cultures were tested for lysis of B-lymphoblastoid cell lines infected with recombinant vaccinia viruses expressing each of nine individual RS virus proteins. The use of peripheral blood dendritic cells to present antigen gave more easily reproducible results over a shorter culture period than conventional methods. The six RS virus proteins most strongly recognized were the nucleoprotein N (nine of nine donors with greater than 10% above background lysis; P = 0.0004), the surface proteins SH (six of nine donors; P = 0.002) and F (five of nine donors; P = 0.008), the matrix proteins M (five of nine donors; P = 0.004) and 22K (three of nine donors; P = 0.01) and the nonstructural protein 1b (six of nine donors; P = 0.004). There was no significant recognition of the major surface glycoprotein G (two of nine donors), the internal phosphoprotein P (one of nine donors), or the nonstructural protein 1c (one of nine donors). Recognition was major histocompatibility complex class I restricted, but no association between major histocompatibility complex phenotype and protein specificity of T cells was seen. Recognition of F and 22K appeared to be associated with recent infection indicated by increased levels of anti-RS virus immunoglobulin G antibody in serum measured by enzyme-linked immunosorbent assay. Since cytotoxic T-cell recognition of RS virus proteins has been demonstrated to be important in the clearance of virus from infected hosts, the N, M, SH, 1b, F, and 22K proteins should be considered potential vaccine components.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1548754      PMCID: PMC289001     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  43 in total

1.  Accidental infection of laboratory worker with recombinant vaccinia virus.

Authors:  P J Openshaw; W H Alwan; A H Cherrie; F M Record
Journal:  Lancet       Date:  1991-08-17       Impact factor: 79.321

2.  Influenza nucleoprotein-specific cytotoxic T-cell clones are protective in vivo.

Authors:  P M Taylor; B A Askonas
Journal:  Immunology       Date:  1986-07       Impact factor: 7.397

3.  Transfer of specific cytotoxic T lymphocytes protects mice inoculated with influenza virus.

Authors:  K L Yap; G L Ada; I F McKenzie
Journal:  Nature       Date:  1978-05-18       Impact factor: 49.962

4.  The 22,000-kilodalton protein of respiratory syncytial virus is a major target for Kd-restricted cytotoxic T lymphocytes from mice primed by infection.

Authors:  P J Openshaw; K Anderson; G W Wertz; B A Askonas
Journal:  J Virol       Date:  1990-04       Impact factor: 5.103

5.  Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein.

Authors:  E L Cooney; A C Collier; P D Greenberg; R W Coombs; J Zarling; D E Arditti; M C Hoffman; S L Hu; L Corey
Journal:  Lancet       Date:  1991-03-09       Impact factor: 79.321

6.  Cell-mediated immune response to respiratory syncytial virus infection: relationship to the development of reactive airway disease.

Authors:  R C Welliver; A Kaul; P L Ogra
Journal:  J Pediatr       Date:  1979-03       Impact factor: 4.406

7.  IgG and IgM antibodies to viral glycoproteins in respiratory syncytial virus infections of graded severity.

Authors:  G L Toms; M S Webb; P D Milner; A D Milner; E G Routledge; R Scott; G M Stokes; A Swarbrick; C E Taylor
Journal:  Arch Dis Child       Date:  1989-12       Impact factor: 3.791

8.  The detection of respiratory syncytial virus in nasopharyngeal aspirates: assessment, formulation, and evaluation of monoclonal antibodies as a diagnostic reagent.

Authors:  A Freke; E J Stott; A P Roome; E O Caul
Journal:  J Med Virol       Date:  1986-02       Impact factor: 2.327

9.  Cytotoxic T-cell response to respiratory syncytial virus in mice.

Authors:  C R Bangham; M J Cannon; D T Karzon; B A Askonas
Journal:  J Virol       Date:  1985-10       Impact factor: 5.103

10.  Human and murine cytotoxic T cells specific to respiratory syncytial virus recognize the viral nucleoprotein (N), but not the major glycoprotein (G), expressed by vaccinia virus recombinants.

Authors:  C R Bangham; P J Openshaw; L A Ball; A M King; G W Wertz; B A Askonas
Journal:  J Immunol       Date:  1986-12-15       Impact factor: 5.422

View more
  51 in total

1.  HLA class I-restricted cytotoxic T-cell epitopes of the respiratory syncytial virus fusion protein.

Authors:  A H Brandenburg; L de Waal; H H Timmerman; P Hoogerhout; R L de Swart; A D Osterhaus
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

2.  Respiratory syncytial virus that lacks open reading frame 2 of the M2 gene (M2-2) has altered growth characteristics and is attenuated in rodents.

Authors:  H Jin; X Cheng; H Z Zhou; S Li; A Seddiqui
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

Review 3.  Animal models of respiratory syncytial virus infection and disease.

Authors:  Randy E Sacco; Russell K Durbin; Joan E Durbin
Journal:  Curr Opin Virol       Date:  2015-07-11       Impact factor: 7.090

4.  Development of a luciferase immunoprecipitation system assay to detect IgG antibodies against human respiratory syncytial virus nucleoprotein.

Authors:  Sangeeta Kumari; Roberta Lynne Crim; Ashwin Kulkarni; Susette A Audet; Thembi Mdluli; Haruhiko Murata; Judy A Beeler
Journal:  Clin Vaccine Immunol       Date:  2014-01-08

Review 5.  Dengue fever virus and Japanese encephalitis virus synthetic peptides, with motifs to fit HLA class I haplotypes prevalent in human populations in endemic regions, can be used for application to skin Langerhans cells to prime antiviral CD8+ cytotoxic T cells (CTLs)--a novel approach to the protection of humans.

Authors:  Y Becker
Journal:  Virus Genes       Date:  1994-09       Impact factor: 2.332

6.  Amino acid variation within the fusion protein of respiratory syncytial virus subtype A and B strains during annual epidemics in South Africa.

Authors:  Elizabeth Agenbach; Caroline T Tiemessen; Marietjie Venter
Journal:  Virus Genes       Date:  2005-03       Impact factor: 2.332

7.  Anti-IL-4 treatment at immunization modulates cytokine expression, reduces illness, and increases cytotoxic T lymphocyte activity in mice challenged with respiratory syncytial virus.

Authors:  Y W Tang; B S Graham
Journal:  J Clin Invest       Date:  1994-11       Impact factor: 14.808

Review 8.  The immune response to respiratory syncytial virus infection: friend or foe?

Authors:  Robert C Welliver
Journal:  Clin Rev Allergy Immunol       Date:  2008-04       Impact factor: 8.667

9.  Enhancement of the CD8+ T cell response to a subdominant epitope of respiratory syncytial virus by deletion of an immunodominant epitope.

Authors:  Hoyin Mok; Sujin Lee; David W Wright; James E Crowe
Journal:  Vaccine       Date:  2008-07-26       Impact factor: 3.641

10.  CD4+ T cells clear virus but augment disease in mice infected with respiratory syncytial virus. Comparison with the effects of CD8+ T cells.

Authors:  W H Alwan; F M Record; P J Openshaw
Journal:  Clin Exp Immunol       Date:  1992-06       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.